Oral ondansetron in the prevention of chemotherapy-induced emesis in breast cancer patients
- 31 December 1995
- journal article
- clinical trial
- Published by Elsevier BV in European Journal of Cancer
- Vol. 31 (1), 15-19
- https://doi.org/10.1016/0959-8049(94)00369-g
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Efficacy of Oral Ondansetron in the Prevention of Emesis in Outpatients Receiving Cyclophosphamide-based ChemotherapyAnnals of Internal Medicine, 1993
- Efficacy of twice daily versus three times daily oral ondansetron in the prevention of chemotherapy induced emesis: A randomized, single-blind, multicentre studyClinical Oncology, 1992
- Ondansetron Compared with Metoclopramide in the Control of Emesis and Quality of Life during Repeated Chemotherapy for Breast CancerOncology, 1992
- Double-blind randomised trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamideEuropean Journal of Cancer and Clinical Oncology, 1991
- Comparison of ondansetron with a combined regimen of alizapride and methylprednisolone in the prophylaxis of cisplatin-induced emesis in patients with lung cancerPublished by Springer Science and Business Media LLC ,1991
- Comparison of the 5-Hydroxytryptamine3(Serotonin) Antagonist Ondansetron (Gr 38032F) with High-Dose Metoclopramide in the Control of Cisplatin-Induced EmesisNew England Journal of Medicine, 1990
- GR38032F, a 5HT3 receptor antagonist, in the prophylaxis of acute cisplatin-induced nausea and vomitingCancer Chemotherapy and Pharmacology, 1989
- A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. French Epirubicin Study Group.Journal of Clinical Oncology, 1988
- Inhibition of cisplatin‐induced vomiting by selective 5‐hydroxytryptamine M‐receptor antagonismBritish Journal of Pharmacology, 1986
- Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation.Journal of Clinical Oncology, 1984